Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline Review, H2 2017’, provides an overview of the Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cognitive Impairment Associated With Schizophrenia (CIAS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Cognitive Impairment Associated With Schizophrenia (CIAS)

The report reviews pipeline therapeutics for Cognitive Impairment Associated With Schizophrenia (CIAS) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Cognitive Impairment Associated With Schizophrenia (CIAS) therapeutics and enlists all their major and minor projects

The report assesses Cognitive Impairment Associated With Schizophrenia (CIAS) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Cognitive Impairment Associated With Schizophrenia (CIAS)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Cognitive Impairment Associated With Schizophrenia (CIAS)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

Amarantus Bioscience Holdings Inc

Astellas Pharma Inc

AstraZeneca Plc

Bristol-Myers Squibb Company

Coronis NeuroSciences Ltd

Eli Lilly and Company

F. Hoffmann-La Roche Ltd

H. Lundbeck A/S

Heptares Therapeutics Ltd

Intra-Cellular Therapies Inc

Iproteos SL

Luc Therapeutics Inc

Neuralstem Inc

Pfizer Inc

Sage Therapeutics Inc

Saniona AB

SK Biopharmaceuticals Co Ltd

Spherium Biomed SL

Suven Life Sciences Ltd

Takeda Pharmaceutical Company Ltd

Vanda Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Cognitive Impairment Associated With Schizophrenia (CIAS) - Overview

Cognitive Impairment Associated With Schizophrenia (CIAS) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Cognitive Impairment Associated With Schizophrenia (CIAS) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cognitive Impairment Associated With Schizophrenia (CIAS) - Companies Involved in Therapeutics Development

AbbVie Inc

Amarantus Bioscience Holdings Inc

Astellas Pharma Inc

AstraZeneca Plc

Bristol-Myers Squibb Company

Coronis NeuroSciences Ltd

Eli Lilly and Company

F. Hoffmann-La Roche Ltd

H. Lundbeck A/S

Heptares Therapeutics Ltd

Intra-Cellular Therapies Inc

Iproteos SL

Luc Therapeutics Inc

Neuralstem Inc

Pfizer Inc

Sage Therapeutics Inc

Saniona AB

SK Biopharmaceuticals Co Ltd

Spherium Biomed SL

Suven Life Sciences Ltd

Takeda Pharmaceutical Company Ltd

Vanda Pharmaceuticals Inc

Cognitive Impairment Associated With Schizophrenia (CIAS) - Drug Profiles

A-431404 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AN-761 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AQW-051 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASP-4345 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASP-5736 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AUT-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AUT-6 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AUT-9 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AVL-3288 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

basmisanil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-955829 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CP-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

davunetide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

eltoprazine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

erteberel - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HTL-9936 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IC-041 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IPR-19 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ITI-214 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LSN-2814617 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LUAF-64280 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NSI-189 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-03463275 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-04958242 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

roflumilast - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SGE-301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SKLA-4R - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize Dopamine D1 Receptor for Cognitive Impairment Associated with Schizophrenia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize NMDA2B for Cognitive Impairment Associated with Schizophrenia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SP-14040 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SUVND-4010 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SUVNG-3031 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAK-041 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAK-058 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAK-831 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VU-0467154 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cognitive Impairment Associated With Schizophrenia (CIAS) - Dormant Projects

Cognitive Impairment Associated With Schizophrenia (CIAS) - Discontinued Products

Cognitive Impairment Associated With Schizophrenia (CIAS) - Product Development Milestones

Featured News & Press Releases

Feb 01, 2015: ASCIL Biopharm cooperates in a Project awarded with a “RETOS-Colaboración” grant

Jan 27, 2015: Spark, a new public-private project created to develop a drug to fight the cognitive impairment associated with schizophrenia

Apr 17, 2013: SK Biopharma Announces FDA's Authorization Of IND For SKL15508 For Treatment Of Cognitive Impairment Associated With Schizophrenia

Feb 19, 2013: Intra-Cellular Therapies Completes Phase I Single Rising Dose Trial Of Selective Phosphodiesterase 1 Inhibitor

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by AbbVie Inc, H2 2017

Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by Amarantus Bioscience Holdings Inc, H2 2017

Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by Astellas Pharma Inc, H2 2017

Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by AstraZeneca Plc, H2 2017

Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by Bristol-Myers Squibb Company, H2 2017

Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by Coronis NeuroSciences Ltd, H2 2017

Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by Eli Lilly and Company, H2 2017

Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by F. Hoffmann-La Roche Ltd, H2 2017

Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by H. Lundbeck A/S, H2 2017

Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by Heptares Therapeutics Ltd, H2 2017

Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by Intra-Cellular Therapies Inc, H2 2017

Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by Iproteos SL, H2 2017

Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by Luc Therapeutics Inc, H2 2017

Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by Neuralstem Inc, H2 2017

Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by Pfizer Inc, H2 2017

Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by Sage Therapeutics Inc, H2 2017

Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by Saniona AB, H2 2017

Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by SK Biopharmaceuticals Co Ltd, H2 2017

Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by Spherium Biomed SL, H2 2017

Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by Suven Life Sciences Ltd, H2 2017

Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017

Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by Vanda Pharmaceuticals Inc, H2 2017

Cognitive Impairment Associated With Schizophrenia (CIAS) – Dormant Projects, H2 2017

Cognitive Impairment Associated With Schizophrenia (CIAS) – Dormant Projects, H2 2017 (Contd..1), H2 2017

Cognitive Impairment Associated With Schizophrenia (CIAS) – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Top 10 Routes of Administration, H2 2017

Number of Products by Stage and Top 10 Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports